Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis

被引:179
作者
Agarwal, K
Czaja, AJ
Jones, DEJ
Donaldson, PT
机构
[1] Univ Newcastle, Sch Med, Fac Clin Med Sci, Liver Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Mayo Clin, Dept Gastroenterol & Hepatol, Rochester, MN USA
关键词
D O I
10.1002/hep.510310110
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Genetic susceptibility to type 1 autoimmune hepatitis is indicated by a preponderance of female subjects and strong associations with human Leukocyte antigens (HLA) DRB1*0301 and DRB1*0401. The gene encoding cytotoxic T-lymphocyte antigen-4 (CTLA-4) on chromosome 2q33 may also influence autoimmunity. To determine the frequency and significance of the exon 1 adenine (A)-guanine (G) base-exchange polymorphism for CTLA-4 in patients with type 1 autoimmune hepatitis, 155 northern European Caucasoid patients and 102 ethnically-matched control subjects were tested by polymerase chain reaction. The genotype distribution was significantly different in patients compared to controls (AA = 50/155 patients vs. 51/102 controls; AG = 84/155 patients vs. 38/102 controls; GG 21/155 patients vs. 13/102 controls, chi(2) = 8.94, P = .011), This difference was caused by a significant over-representation of the G allele in patients compared to controls (105/155 patients vs. 51/102 controls, chi(2) = 8.34, P = .004, odds ratio = 2.12). The GG genotype was associated with a significantly higher mean serum aspartate transaminase level (P = .03), greater frequency of antibodies to thyroid microsomal antigens (P = .004) and was found more commonly in patients with HLA DRB1*0301 (P = .02), Treatment outcomes, however, were not affected by the genotype, The CTLA-4 G allele is more common in patients with type 1 autoimmune hepatitis and may represent a second susceptibility allele, Furthermore, there may be synergy between the HLA-DRB1*0301 and the GG genotype in terms of disease risk.
引用
收藏
页码:49 / 53
页数:5
相关论文
共 41 条
[41]  
WHITTINGHAM S, 1981, CLIN EXP IMMUNOL, V43, P80